Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
SNAI2
REST API REST API
Homo sapiens
SNAI2 is differentially expressed in 239 experiments: 170 organism parts: uterus, adipose tissue, ... (168 more);, 205 disease states: normal, glioblastoma, ... (203 more);, 96 cell types 431 cell lines 35 compound treatments and 52 other conditions.
Synonyms SLUG, SLUGH1, SNAIL2
Orthologs ENSGALG00000015241 (Gallus gallus)   snai2 (Danio rerio)   SNAI2_BOVIN (Bos taurus)   ENSGALG00000022403 (Gallus gallus)   Snai2 (Mus musculus)   wor (Drosophila melanogaster)   esg (Drosophila melanogaster)   sna (Drosophila melanogaster)   snai2 (Xenopus laevis)   A5HBK7_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cell migration, regulation of transcription, DNA-dependent, cytoplasm, nuclear chromatin, intracellular, negative regulation of apoptosis, metal ion binding, nucleic acid binding, sequence-specific DNA binding, multicellular organismal development, sensory perception of sound, positive regulation of histone acetylation, nucleus, canonical Wnt receptor signaling pathway, chromatin binding, negative regulation of transcription from RNA polymerase II promoter, epithelial to mesenchymal transition, response to radiation, zinc ion binding, negative regulation of cell adhesion mediated by integrin, positive regulation of survival gene product expression, neural crest cell development, positive regulation of cell migration, osteoblast differentiation, cartilage morphogenesis, pigmentation, negative regulation of cell adhesion involved in substrate-bound cell migration, regulation of osteoblast differentiation, negative regulation of chondrocyte differentiation, epithelium development, palate development, negative regulation of canonical Wnt receptor signaling pathway, positive regulation of fat cell differentiation, negative regulation of DNA damage response, signal transduction by p53 class mediator, white fat cell differentiation, negative regulation of vitamin D biosynthetic process, negative regulation of keratinocyte proliferation, desmosome disassembly, epithelial to mesenchymal transition involved in endocardial cushion formation, RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in negative regulation of transcription, cellular response to epidermal growth factor stimulus, regulation of chemokine production, negative regulation of vitamin D receptor signaling pathway, negative regulation of catenin import into nucleus, cellular response to ionizing radiation, negative regulation of stem cell proliferation, sequence-specific distal enhancer binding RNA polymerase II transcription factor activity
InterPro Term Znf_C2H2-like, Znf_C2H2
UniProt Accession O43623, C9JS24
Gene-Disease Assocation PIEBALD TRAIT; PBT, WAARDENBURG SYNDROME, TYPE 2D; WS2D
Search EB-eye ENSG00000019549
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-GEOD-1577, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (34 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
BT474
2
E-MTAB-37, E-MTAB-62
CCRFCEM
2
E-MTAB-37, E-GEOD-24147
DU145
2
E-GEOD-17482, E-GEOD-20089
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MCF-10A
2
E-GEOD-14990, E-TABM-420
425 more value(s).


Cell type

studied in E-GEOD-20193, E-MEXP-2426, E-GEOD-21668, E-GEOD-19397, E-GEOD-3920, ... (41 experiments)

Factor Value U/D Experiments
embryonic stem cell
3
E-MEXP-930, E-GEOD-2248, E-MEXP-2426
induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
kidney cell
1
E-MEXP-1216
primary smooth muscle cell
1
E-MEXP-66
erythrocyte
1
E-MEXP-583
CD33+ myeloid
1
E-AFMX-5
90 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-GEOD-1577, E-GEOD-16363, E-MTAB-62, ... (49 experiments)

Factor Value U/D Experiments
glioblastoma
1
4
E-GEOD-6014, E-GEOD-4290, E-MTAB-37, E-MEXP-567, E-GEOD-4412 ... (5 experiments)
prostate carcinoma
1
4
E-MEXP-2034, E-TABM-26, E-GEOD-96, E-MEXP-1327, E-GEOD-3868 ... (5 experiments)
colon carcinoma
3
E-MTAB-62, E-MTAB-37, E-GEOD-3726
control
3
E-GEOD-21912, E-GEOD-20602, E-GEOD-16363
chondrosarcoma
2
E-MTAB-62, E-MTAB-37
head and neck squamous cell carcinoma
2
E-MTAB-62, E-GEOD-6631
199 more value(s).


Compound treatment

studied in E-MEXP-2449, E-GEOD-1417, E-TABM-782, E-GEOD-12438, E-GEOD-697, ... (23 experiments)

Factor Value U/D Experiments
control for heregulin
1
E-GEOD-6462
dimethyl sulfoxide
1
E-GEOD-6932
mercaptopurine, methotrexate
1
E-GEOD-412
lipopolysaccharide
1
E-TABM-868
hydrogen peroxide
1
E-GEOD-5339
unknown
1
E-GEOD-7307
29 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-19246, E-GEOD-2034, ... (7 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-20033, E-GEOD-3140, E-MEXP-2283, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-TABM-147

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

Ethnicity
studied in E-GEOD-6919, E-GEOD-21589, E-GEOD-16363

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-7578, E-GEOD-20847, E-MEXP-2340, ... (7 experiments)

Genotype
studied in E-GEOD-1923, E-GEOD-2466, E-GEOD-17476, E-MEXP-1274, E-GEOD-22593, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-2657, E-GEOD-20540, E-GEOD-20504, E-GEOD-9764, ... (7 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-TABM-176, E-GEOD-1926, E-GEOD-19330, E-GEOD-6919, ... (21 experiments)

Infection
studied in E-GEOD-9723, E-GEOD-6927, E-GEOD-6802

Karyotype
studied in E-GEOD-7214

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750, E-GEOD-1657, E-GEOD-2487, E-GEOD-4600

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254

RNAi
studied in E-MEXP-2115, E-MEXP-1509, E-MEXP-101, E-MEXP-548, E-GEOD-3697, ... (8 experiments)

Sample type
studied in E-TABM-783

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-11428

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-16837

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271

Processing time: 0.392 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM